These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 35451946)
1. Molecular identification and antifungal susceptibility of clinically relevant and cryptic species of Nargesi S; Jafarzadeh J; Najafzadeh MJ; Nouripour-Sisakht S; Haghani I; Abastabar M; Ilkit M; Hedayati MT J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451946 [No Abstract] [Full Text] [Related]
2. Species distribution and antifungal susceptibility of clinical Aspergillus isolates: A multicentre study in Taiwan, 2016-2020. Wang HC; Hsieh MI; Choi PC; Wu WL; Wu CJ; Mycoses; 2023 Aug; 66(8):711-722. PubMed ID: 37186489 [TBL] [Abstract][Full Text] [Related]
3. Aspergillus welwitschiae; an otomycosis predominant agent, new epidemiological and antifungal susceptibility data from Iran. Halvaeezadeh M; Jalaee GA; Fatahinia M; Mahmoudabadi AZ Microb Pathog; 2023 Aug; 181():106180. PubMed ID: 37257666 [TBL] [Abstract][Full Text] [Related]
4. Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents. Badiee P; Boekhout T; Zarei Mahmoudabadi A; Mohammadi R; Ayatollahi Mousavi SA; Najafzadeh MJ; Soltani J; Hashemi J; Diba K; Ghadimi-Moghadam A; Salimi-Khorashad AR; Shokohi T; Amin Shahidi M; Ghasemi F; Jafarian H Microbiol Spectr; 2022 Jun; 10(3):e0253921. PubMed ID: 35579442 [TBL] [Abstract][Full Text] [Related]
5. Drug Sensitivity and Resistance Mechanism in Aspergillus Section Hashimoto A; Hagiwara D; Watanabe A; Yahiro M; Yikelamu A; Yaguchi T; Kamei K Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607016 [No Abstract] [Full Text] [Related]
6. Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 Carrara B; Richards R; Imbert S; Morio F; Sasso M; Zahr N; Normand AC; Le Pape P; Lachaud L; Ranque S; Maubon D; Piarroux R; Fekkar A Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32312779 [No Abstract] [Full Text] [Related]
7. In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex. Badali H; Fakhim H; Zarei F; Nabili M; Vaezi A; Poorzad N; Dolatabadi S; Mirhendi H Mycopathologia; 2016 Apr; 181(3-4):235-40. PubMed ID: 26615417 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species. Wang HC; Hsieh MI; Choi PC; Wu CJ J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391 [TBL] [Abstract][Full Text] [Related]
9. Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait. Al-Wathiqi F; Ahmad S; Khan Z BMC Infect Dis; 2013 Mar; 13():126. PubMed ID: 23496810 [TBL] [Abstract][Full Text] [Related]
10. The Molecular Identification and Antifungal Susceptibility of Clinical Isolates of Djenontin E; Costa JM; Mousavi B; Nguyen LDN; Guillot J; Delhaes L; Botterel F; Dannaoui E Microorganisms; 2023 Sep; 11(10):. PubMed ID: 37894087 [TBL] [Abstract][Full Text] [Related]
11. Species identification and antifungal susceptibility testing of Aspergillus strains isolated from patients with otomycosis in northern China. Jing R; Yang WH; Xiao M; Li Y; Zou GL; Wang CY; Li XW; Xu YC; Hsueh PR J Microbiol Immunol Infect; 2022 Apr; 55(2):282-290. PubMed ID: 33839057 [TBL] [Abstract][Full Text] [Related]
12. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses. Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621 [TBL] [Abstract][Full Text] [Related]
13. Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients. Kamali Sarwestani Z; Hashemi SJ; Rezaie S; Gerami Shoar M; Mahmoudi S; Elahi M; Bahardoost M; Tajdini A; Abutalebian S; Daie Ghazvini R J Mycol Med; 2018 Jun; 28(2):279-284. PubMed ID: 29540288 [TBL] [Abstract][Full Text] [Related]
14. Discovery of Tolerance to Itraconazole in Japanese Isolates of Aspergillus Section Nigri, Aspergillus tubingensis and Aspergillus welwitschiae, by Microscopic Observation. Matsumoto Y; Suzuki M; Nihei H; Matsumoto S Med Mycol J; 2022; 63(3):65-69. PubMed ID: 36047184 [TBL] [Abstract][Full Text] [Related]
15. Cryptic species and azole resistance in the Aspergillus niger complex. Howard SJ; Harrison E; Bowyer P; Varga J; Denning DW Antimicrob Agents Chemother; 2011 Oct; 55(10):4802-9. PubMed ID: 21768508 [TBL] [Abstract][Full Text] [Related]
16. Species identification, antifungal susceptibility, and clinical feature association of Aspergillus section Nigri isolates from the lower respiratory tract. Takeda K; Suzuki J; Watanabe A; Matsuki M; Higa K; Inoue E; Akashi S; Shimada M; Kawashima M; Ohshima N; Fukami T; Masuda K; Yamane A; Tamura A; Nagai H; Matsui H; Tohma S; Kamei K Med Mycol; 2020 Apr; 58(3):310-314. PubMed ID: 31240316 [TBL] [Abstract][Full Text] [Related]
17. In vitro activities of five antifungal agents against 199 clinical and environmental isolates of Aspergillus flavus, an opportunistic fungal pathogen. Khodavaisy S; Badali H; Hashemi SJ; Aala F; Nazeri M; Nouripour-Sisakht S; Sorkherizi MS; Amirizad K; Aslani N; Rezaie S J Mycol Med; 2016 Jun; 26(2):116-121. PubMed ID: 26948143 [TBL] [Abstract][Full Text] [Related]
18. Species Distribution and In Vitro Azole Susceptibility of Aspergillus Section Nigri Isolates from Clinical and Environmental Settings. Iatta R; Nuccio F; Immediato D; Mosca A; De Carlo C; Miragliotta G; Parisi A; Crescenzo G; Otranto D; Cafarchia C J Clin Microbiol; 2016 Sep; 54(9):2365-72. PubMed ID: 27413191 [TBL] [Abstract][Full Text] [Related]
19. Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China. Zhang L; Wang X; Houbraken J; Mei H; Liao W; Hasimu H; Liu W; Deng S Mycopathologia; 2020 Jun; 185(3):527-535. PubMed ID: 32346838 [TBL] [Abstract][Full Text] [Related]
20. Antifungal susceptibility profile and molecular identification of Cyp51C mutations in clinical and environmental isolates of Aspergillus flavus from Argentina. Hermida-Alava K; Brito Devoto T; Sautua F; Gordó M; Scandiani M; Formento N; Luque A; Carmona M; Cuestas ML Mycoses; 2021 Jan; 64(1):95-101. PubMed ID: 33001518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]